MoonLake Immunotherapeutics MLTX shares are up during Monday’s premarket session following the announcement of positive topline results from its Phase 2 clinical trial of sonelokimab in treating axial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results